Tag: Clinical Trial
Breaking News
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of BioVie Inc. (BIVI) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on...
A Child Born Deaf Can Hear for the First Time Thanks to Pioneering Gene Therapy
When Aissam Dam had the strange device connected to his ear, he had no idea it was going to change his life.An 11-year-old boy,...
Focused ultrasound plus plaque-reducing drugs could slow Alzheimer’s progression – Physics World
<a href="https://coingenius.news/wp-content/uploads/2024/01/focused-ultrasound-plus-plaque-reducing-drugs-could-slow-alzheimers-progression-physics-world-3.jpg" data-fancybox data-src="https://coingenius.news/wp-content/uploads/2024/01/focused-ultrasound-plus-plaque-reducing-drugs-could-slow-alzheimers-progression-physics-world-3.jpg" data-caption="Deliver the drugs Researchers at the West Virginia University Rockefeller Neuroscience Institute, shown in the MRI...
New Research Reveals Status of AI/ML Adoption Amid Surging Interest for Clinical Trial Leaders in 2024
Annual life science industry report by eClinical Solutions uncovers trends and practical realities for external data, AI, and cycle times
BOSTON–(BUSINESS WIRE)–eClinical Solutions, a global...
“The Time is Now” to Maximize Human Healthspan: A Discussion with Peter Diamandis, Hans Keirstead, Daniel Kraft and Jane Metcalfe
IRVINE, Calif.–(BUSINESS WIRE)–#ClinicalTrials—Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, presents a one-of-a-kind film (The Time...
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Strasbourg, France & Tokyo, Japan, Jan 9, 2024 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based...
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
ZELSUVMI™ is expected to be commercially available during the second half of 2024
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S....
MouthWatch Marks 2023 a Year of Virtual-First Care Innovation and Leading Intraoral Photography Growth
METUCHEN, N.J.–(BUSINESS WIRE)–MouthWatch, LLC, an industry leader in teledentistry solutions and dental intraoral cameras, is marking 2023 as a year defined by its commitment...
US Clinical Trial Data Management Service Market Focused Insights 2023-2028, with Profiles of Key Vendors IQVIA, SYNEOS, ICON & Labcorp – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “US Clinical Trial Data Management Service Market – Focused Insights 2023-2028” report has been added to ResearchAndMarkets.com’s offering.
There are over 8000 clinical...
CRISPR Gene Editing Had a Breakthrough Year—and It’s Only Getting Started
CRISPR ended 2023 with a bang.In November, the gene editing tool scored its first clinical approval for treating sickle cell anemia and beta-thalassemia in...
After Weight Loss, Ozempic Is Set to Conquer a Universe of Brain Disorders
One inescapable word dominated biomedicine this year: Ozempic.Physicians were amazed at the drug’s efficacy in treating diabetes, for which it is FDA approved, and...
Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders
SAN FRANCISCO–(BUSINESS WIRE)–#biotech—Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of...
Latest Intelligence
